Literature DB >> 15947034

Hypocretin-1 (orexin-A) facilitates inhibitory and diminishes excitatory synaptic pathways to cardiac vagal neurons in the nucleus ambiguus.

Olga Dergacheva1, Xin Wang, Zheng-Gui Huang, Evguenia Bouairi, Christopher Stephens, Chistopher Gorini, David Mendelowitz.   

Abstract

Hypocretin-1 is a neuropeptide recently shown to be involved in autonomic regulation. Hypocretin-1 is expressed by hypothalamic neurons, which project to many regions of the central nervous system, including the nucleus ambiguus. One possible site of action of hypocretin-1 could be cardioinhibitory parasympathetic vagal neurons within the nucleus ambiguus. This study examines whether hypocretin-1 modulates inhibitory and excitatory postsynaptic currents in cardiac vagal neurons in the rat nucleus ambiguus. GABAergic, glycinergic, and glutamatergic activity to cardiac vagal neurons was examined using whole-cell patch-clamp recordings in an in vitro brain slice preparation. Hypocretin-1 (1 microM) produced a significant increase in the frequency and amplitude of both GABAergic and glycinergic inhibitory postsynaptic currents and a significant decrease in the frequency of glutamatergic excitatory postsynaptic currents. Application of tetrodotoxin (0.5 microM) blocked all of the responses to hypocretin-1, indicating the changes in neurotransmission with hypocretin-1 do not occur at presynaptic terminals but rather occur at the preceding GABAergic, glycinergic, and glutamatergic neurons that project to cardiac vagal neurons. The increase in GABAergic and glycinergic inhibitory postsynaptic currents, and the decrease in glutamatergic excitatory postsynaptic currents, could be mechanisms by which hypocretin-1 affects heart rate and cardiac function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15947034     DOI: 10.1124/jpet.105.086421

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

Review 1.  Energy expenditure: role of orexin.

Authors:  Jennifer A Teske; Vijayakumar Mavanji
Journal:  Vitam Horm       Date:  2012       Impact factor: 3.421

Review 2.  Parasympathetic Vagal Control of Cardiac Function.

Authors:  Jhansi Dyavanapalli; Olga Dergacheva; Xin Wang; David Mendelowitz
Journal:  Curr Hypertens Rep       Date:  2016-03       Impact factor: 5.369

3.  Orexin/hypocretin receptor signalling: a functional perspective.

Authors:  C S Leonard; J P Kukkonen
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 4.  The hypocretins/orexins: integrators of multiple physiological functions.

Authors:  Jingcheng Li; Zhian Hu; Luis de Lecea
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

5.  Effects of VPAC1 activation in nucleus ambiguus neurons.

Authors:  Florin Liviu Gherghina; Andrei Adrian Tica; Elena Deliu; Mary E Abood; G Cristina Brailoiu; Eugen Brailoiu
Journal:  Brain Res       Date:  2016-12-30       Impact factor: 3.252

6.  Orexinergic modulation of GABAergic neurotransmission to cardiac vagal neurons in the brain stem nucleus ambiguus changes during development.

Authors:  O Dergacheva; R Bateman; P Byrne; D Mendelowitz
Journal:  Neuroscience       Date:  2012-02-21       Impact factor: 3.590

7.  Direct projections from hypothalamic orexin neurons to brainstem cardiac vagal neurons.

Authors:  Olga Dergacheva; Akihiro Yamanaka; Alan R Schwartz; Vsevolod Y Polotsky; David Mendelowitz
Journal:  Neuroscience       Date:  2016-09-28       Impact factor: 3.590

8.  State-dependent control of lumbar motoneurons by the hypocretinergic system.

Authors:  Jack Yamuy; Simon J Fung; Mingchu Xi; Michael H Chase
Journal:  Exp Neurol       Date:  2009-12-03       Impact factor: 5.330

Review 9.  Hypothalamic orexins/hypocretins as regulators of breathing.

Authors:  Rhîannan H Williams; Denis Burdakov
Journal:  Expert Rev Mol Med       Date:  2008-10-02       Impact factor: 5.600

10.  The role of spinal orexin-1 receptors in posterior hypothalamic modulation of neuropathic pain.

Authors:  Y Jeong; J E Holden
Journal:  Neuroscience       Date:  2009-02-11       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.